India's Race For Lipitor: More Than Five Players May Blunt Generic Gains In Post-Exclusivity Period
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - Two years after Pfizer Inc. filed a patent infringement lawsuit against India's Dr. Reddy's Laboratories Ltd. in a bid to ward off threats to its blockbuster brand Lipitor (atorvastatin), the two companies filed a joint motion Aug. 19 to dismiss the case at the U.S. District Court of Delaware. The case was dismissed Aug. 29 but the terms and conditions of the settlement and a likely launch date for the generic versions of Dr. Reddy's product were not disclosed
You may also be interested in...
Ranbaxy Chairman Says No Change To Lipitor Generic Launch Timeline In U.S.; Dismisses Speculation Of $1 Bn FDA Penalty
MUMBAI - Share prices of Ranbaxy Laboratories Ltd. rose nearly 5% on an otherwise flat day of trading at the Bombay Stock Exchange backed by news that the company is "on schedule" to launch generic versions of Lipitor (atorvastatin) in the United States
Ranbaxy Chairman Says No Change To Lipitor Generic Launch Timeline In U.S.; Dismisses Speculation Of $1 Bn FDA Penalty
MUMBAI - Share prices of Ranbaxy Laboratories Ltd. rose nearly 5% on an otherwise flat day of trading at the Bombay Stock Exchange backed by news that the company is "on schedule" to launch generic versions of Lipitor (atorvastatin) in the United States
Will Ranbaxy Tie Up With Teva To Launch Generic Lipitor?
MUMBAI - Breaking a long silence, Ranbaxy Laboratories Ltd. Managing Director Arun Sawhney told investors last week that he is "very optimistic" about keeping the U.S. launch date of generic versions of Lipitor (atorvastatin), the largest pharmaceutical brand